Evommune, Inc. - EVMN

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Feb 19, 2026 SCHEDULE 13D/A — 14.7% — View
Feb 17, 2026 SCHEDULE 13D/A — — — View
Feb 13, 2026 SCHEDULE 13G Nan Fung Group Holdings Limited 10.9% 3,435,599 View
Feb 13, 2026 SCHEDULE 13G NF Investment Holdings Limited 10.7% 3,367,975 View
Feb 13, 2026 SCHEDULE 13G Nan Fung Life Sciences Holdings Limited 10.7% 3,367,975 View
Feb 13, 2026 SCHEDULE 13G NFLS Platform Holdings Limited 4.6% 1,441,032 View
Feb 13, 2026 SCHEDULE 13G NFLS Delta III Limited 4.6% 1,441,032 View
Feb 13, 2026 SCHEDULE 13G Pivotal Life Sciences Holdings Limited 6.1% 1,926,943 View
Feb 13, 2026 SCHEDULE 13G Pivotal Partners Ltd 6.1% 1,926,943 View
Feb 13, 2026 SCHEDULE 13G Pivotal bioVenture Partners Fund I U.G.P. Ltd. 5.2% 1,632,441 View
Feb 13, 2026 SCHEDULE 13G Pivotal bioVenture Partners Fund I G.P., L.P. 5.2% 1,632,441 View
Feb 13, 2026 SCHEDULE 13G Pivotal bioVenture Partners Fund I, L.P. 5.2% 1,632,441 View
Feb 13, 2026 SCHEDULE 13G Pivotal bioVenture Partners Fund II G.P. Ltd 0.9% 294,502 View
Feb 13, 2026 SCHEDULE 13G Pivotal bioVenture Partners Fund II, L.P. 0.9% 294,502 View
Feb 13, 2026 SCHEDULE 13G NFLS Delta Limited 4.6% 1,441,032 View
Nov 17, 2025 SCHEDULE 13D — 20.0% — View
Nov 17, 2025 SCHEDULE 13G Andera Partners 6.0% 1,897,362 View
Nov 17, 2025 SCHEDULE 13G BioDiscovery 6 FPCI 6.0% 1,897,362 View
Nov 17, 2025 SCHEDULE 13G Stephane Bergez 6.0% 1,897,362 View
Nov 17, 2025 SCHEDULE 13G Francois Xavier Mauron 6.0% 1,897,362 View
Nov 14, 2025 SCHEDULE 13D — 20.0% — View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.